title: Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
abstract: OBJECTIVE
  To compare the diagnostic accuracy of (111)In-pentetreotide-scintigraphy with (68)Ga-DOTATOC-positron emission tomography (PET)/computed tomography (CT) in patients with metastatic-neuroendocrine tumour (NET) scheduled for peptide receptor radionuclide therapy (PRRT). Incremental lesions (ILs) were defined as lesions observed on only one modality.
  
  
  METHODS
  Fifty-three metastatic-NET-patients underwent (111)In-pentetreotide-scintigraphy (24 h post-injection; planar+single-photon emission CT (SPECT) abdomen) and whole-body (68)Ga-DOTATOC-PET/CT. SPECT and PET were compared in a lesion-by-lesion and organ-by-organ analysis, determining the total lesions and ILs for both modalities.
  
  
  RESULTS
  Significantly more lesions were detected on (68)Ga-DOTATOC-PET/CT versus (111)In-pentetreotide-scintigraphy. More specifically, we observed 1,098 lesions on PET/CT (range: 1-105; median: 15) versus 660 on SPECT (range: 0-73, median: 9) (p<0.0001), with 439 PET-ILs (42/53 patients) and one SPECT-IL (1/53 patients). The sensitivity for PET/CT was 99.9 % (95 % CI, 99.3-100.0), for SPECT 60.0 % (95 % CI, 48.5-70.2). The organ-by-organ analysis showed that the PET-ILs were most frequently visualized in liver and skeleton.
  
  
  CONCLUSIONS
  Ga-DOTATOC-PET/CT is superior for the detection of NET-metastases compared to (111)In-pentetreotide SPECT.
  
  
  CONCLUSIONS
  Somatostatin receptor PET is superior to SPECT in detecting NET metastases. PET is the scintigraphic method for accurate depiction of NET tumour burden. The sensitivity of PET is twofold higher than the sensitivity of SPECT.
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Van Binnebeek
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Vanbilloen
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Baete
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Terwinghe
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Koole
authors.affiliation: Department of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.|Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.
authors.forename: F M
authors.initials: FM
authors.lastname: Mottaghy
authors.affiliation: Medical Oncology, University Hospitals Leuven and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.
authors.forename: P M
authors.initials: PM
authors.lastname: Clement
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Mortelmans
authors.affiliation: Department of Public Health and Primary Care (I-BioStat), KU Leuven and UHasselt, Leuven, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Bogaerts
authors.affiliation: Radiation Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Haustermans
authors.affiliation: Pulmonology, University Hospitals Leuven, Leuven, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Nackaerts
authors.affiliation: Division of Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium.
authors.forename: E
authors.initials: E
authors.lastname: Van Cutsem
authors.affiliation: Division of Digestive Oncology, University Hospitals Leuven and Department of Oncology, KU Leuven, Leuven, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Verslype
authors.affiliation: Laboratory for Radiopharmacy, KU Leuven, Leuven, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Verbruggen
authors.affiliation: Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.|Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium. christophe.deroose@uzleuven.be.
authors.forename: C M
authors.initials: CM
authors.lastname: Deroose
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary; D005260:Female; D005710:Gallium Radioisotopes; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000556:secondary; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000532:radiotherapy; D015282:Octreotide / Q000031:analogs & derivatives; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013004:Somatostatin / Q000031:analogs & derivatives; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D013004:Somatostatin; C081788:pentetreotide; D015282:Octreotide; C106246:Edotreotide
keywords: 111In-pentetreotide; 68Ga-DOTATOC; Neuroendocrine tumour; PRRT; SPECT